Base de dados : MEDLINE
Pesquisa : D12.776.260.532 [Categoria DeCS]
Referências encontradas : 488 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 49 ir para página                         

  1 / 488 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381393
[Au] Autor:Ding M; Pan J; Guo Z; Liu Q; Yang C; Mao L
[Ad] Endereço:a Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou University , Xuzhou , China.
[Ti] Título:SATB1 is a Novel Molecular Target for Cancer Therapy.
[So] Source:Cancer Invest;36(1):28-36, 2018 Jan 02.
[Is] ISSN:1532-4192
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The special AT-rich sequence binding-protein1 (SATB1) attracts excessive attention due to its high expression in a variety of malignancies. SATB1 reprograms chromatin and transcription profiles to promote tumor cell growth and invasion and inhibit apoptosis, leading to tumor progression and metastasis. Consistently, silencing SATB1 with small interfering RNA inhibits the growth and invasion of some kinds of tumors. In this review, we highlight recent progress in our understanding of the role of SATB1 as global regulator of gene expression during cancer development, and evaluate the potential of SATB1 as a molecular therapeutic target for cancers with aberrant SATB1 expression.
[Mh] Termos MeSH primário: Proteínas de Ligação à Região de Interação com a Matriz/genética
Neoplasias/genética
[Mh] Termos MeSH secundário: Animais
Proliferação Celular/genética
Regulação Neoplásica da Expressão Gênica/genética
Seres Humanos
Terapia de Alvo Molecular/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Matrix Attachment Region Binding Proteins)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180131
[St] Status:MEDLINE
[do] DOI:10.1080/07357907.2018.1423688


  2 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374710
[Au] Autor:Sliwinska-Jewsiewicka A; Kowalczyk AE; Krazinski BE; Godlewski J; Kwiatkowski P; Kiewisz J; Grzegrzolka J; Dziegiel P; Kmiec Z
[Ad] Endereço:Department of Human Histology and Embryology, School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
[Ti] Título:Decreased Expression of SATB2 Associates with Tumor Growth and Predicts Worse Outcome in Patients with Clear Cell Renal Cell Carcinoma.
[So] Source:Anticancer Res;38(2):839-846, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: SATB2 (special AT-rich sequence-binding protein 2) is a DNA-binding protein that is involved in transcriptional regulation and chromatin remodeling. SATB2 protein has been described as a promising novel marker in several human cancers. PATIENTS AND METHODS: This study compared SATB2 expression in tumor and matched unchanged renal tissues collected from 57 patients with clear cell renal cell carcinoma (ccRCC). SATB2 mRNA levels were determined by quantitative polymerase chain reaction, while SATB2 protein expression was estimated by immunohistochemistry. Moreover, the associations between SATB2 expression in ccRCC samples and clinicopathological and survival data of the patients were investigated. RESULTS: The mRNA level of SATB2 was lower in tumor tissues than in samples of corresponding unchanged kidney. Although the average immunoreactivity of SATB2 protein did not differ significantly between cancer cells and epithelial cells of proximal convoluted tubules, the decreased SATB2 expression in tumor specimens inversely correlated with the size of primary tumor and predicted worse patients' outcome. CONCLUSION: The results of the presented study suggest the tumor-suppressing function of SATB2 and that the expression level of this protein can be considered a potential prognostic factor in ccRCC.
[Mh] Termos MeSH primário: Carcinoma de Células Renais/metabolismo
Neoplasias Renais/metabolismo
Proteínas de Ligação à Região de Interação com a Matriz/biossíntese
Fatores de Transcrição/biossíntese
[Mh] Termos MeSH secundário: Idoso
Carcinoma de Células Renais/genética
Carcinoma de Células Renais/patologia
Estudos de Casos e Controles
Processos de Crescimento Celular/fisiologia
Feminino
Seres Humanos
Imuno-Histoquímica
Neoplasias Renais/genética
Neoplasias Renais/patologia
Masculino
Proteínas de Ligação à Região de Interação com a Matriz/genética
Meia-Idade
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
Taxa de Sobrevida
Fatores de Transcrição/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Matrix Attachment Region Binding Proteins); 0 (RNA, Messenger); 0 (SATB2 protein, human); 0 (Transcription Factors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  3 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29374696
[Au] Autor:Glatzel-Plucinska N; Piotrowska A; Grzegrzolka J; Olbromski M; Rzechonek A; Dziegiel P; Podhorska-Okolow M
[Ad] Endereço:Department of Histology and Embryology, Medical University, Wroclaw, Poland.
[Ti] Título:SATB1 Level Correlates with Ki-67 Expression and Is a Positive Prognostic Factor in Non-small Cell Lung Carcinoma.
[So] Source:Anticancer Res;38(2):723-736, 2018 02.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Non-small cell lung carcinomas (NSCLCs), mainly adenocarcinoma (AC) and squamous cell carcinoma (LSCC), account for about 80% of all lung cancer cases. One of the proteins involved in NSCLC progression may be special AT-rich binding protein 1 (SATB1), a potent transcriptional regulator, able to control the expression of whole sets of genes simultaneously. SATB1 has been found to be associated with aggressive phenotype and poor prognosis in numerous malignancies, including breast, colon, ovary and prostate cancer. However, its role in NSCLC is still not fully understood. The aim of this study was to investigate the expression of SATB1 protein and mRNA in NSCLC and non-malignant lung tissue (NMLT) samples, as well as to determine possible relationships of SATB1 expression with both the expression of Ki-67 and the clinicopathological data of the patients. MATERIALS AND METHODS: The study was performed on 277 NSCLC (158 AC, 119 LSCC) and 20 NMLT samples. RESULTS: We observed increased SATB1 immunoreactivity in NSCLC when compared to NMLT, and in LSCC when compared to AC cases. We also noted that an elevated SATB1 immunoreactivity was associated with a poor degree of AC differentiation, whereas in LSCC, an inverse relationship was observed. Our analyses revealed that the expression of SATB1 positively correlated with Ki-67 index in NSCLC and LSCC, but not in AC cases. Finally, we found that high SATB1 expression was associated with a better overall survival of patients with NSCLC. CONCLUSION: SATB1 plays diverse roles in different NSCLC subtypes, and its expression may have a prognostic significance for patients with these tumours.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/metabolismo
Antígeno Ki-67/metabolismo
Neoplasias Pulmonares/metabolismo
Proteínas de Ligação à Região de Interação com a Matriz/metabolismo
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Biomarcadores Tumorais/genética
Biomarcadores Tumorais/metabolismo
Carcinoma Pulmonar de Células não Pequenas/genética
Carcinoma Pulmonar de Células não Pequenas/mortalidade
Carcinoma Pulmonar de Células não Pequenas/patologia
Estudos de Coortes
Feminino
Fibroblastos/metabolismo
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Estimativa de Kaplan-Meier
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/mortalidade
Neoplasias Pulmonares/patologia
Masculino
Proteínas de Ligação à Região de Interação com a Matriz/genética
Meia-Idade
Prognóstico
Análise Serial de Tecidos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Ki-67 Antigen); 0 (Matrix Attachment Region Binding Proteins); 0 (SATB1 protein, human)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180129
[St] Status:MEDLINE


  4 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29196257
[Au] Autor:Wang J; Lu Y; Ding H; Gu T; Gong C; Sun J; Zhang Z; Zhao Y; Ma C
[Ad] Endereço:Zhangjiagang First People 's Hospital, Zhangjiagang Hospital Affiliated to Suzhou University, Zhangjiagang 215600, China.
[Ti] Título:The miR-875-5p inhibits SATB2 to promote the invasion of lung cancer cells.
[So] Source:Gene;644:13-19, 2018 Feb 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The pathogenesis of non-small cell lung cancer (NSCLC) is regulated by various miRNAs. In this study, we identified that miR-875-5pis up-regulated in NSCLC patients, and inhibited SATB Homeobox 2(SATB2) to promote proliferation and invasion of NSCLCcells.CCK-8assay revealed thatmiR-875-5p mimics promoted proliferation of NSCLC cells. Transwell assay showed that miR-875-5pmimicspromoted the invasion and migration of NSCLC cells. Luciferase assays confirmed that miR-875-5pdirectly binds to the 3'untranslated region of SATB2, and western blotting showed that miR-875-5psuppresses the expression of SATB2 at the protein level. Moreover, the inhibitors of miR-875-5pinhibit proliferation and invasion of NSCLC cell lines. The miR-875-5pwouldbe a potential therapeutic target for NSCLC treatment in the future.
[Mh] Termos MeSH primário: Neoplasias Pulmonares/genética
Neoplasias Pulmonares/patologia
Proteínas de Ligação à Região de Interação com a Matriz/genética
MicroRNAs/genética
Invasividade Neoplásica/genética
Fatores de Transcrição/genética
[Mh] Termos MeSH secundário: Regiões 3' não Traduzidas/genética
Idoso
Carcinoma Pulmonar de Células não Pequenas/genética
Carcinoma Pulmonar de Células não Pequenas/patologia
Linhagem Celular Tumoral
Movimento Celular/genética
Proliferação Celular/genética
Feminino
Seres Humanos
Pulmão/patologia
Masculino
Regulação para Cima/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3' Untranslated Regions); 0 (MIRN-875 microRNA, human); 0 (Matrix Attachment Region Binding Proteins); 0 (MicroRNAs); 0 (SATB2 protein, human); 0 (Transcription Factors)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180119
[Lr] Data última revisão:
180119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171203
[St] Status:MEDLINE


  5 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968158
[Au] Autor:Berg KB; Schaeffer DF
[Ti] Título:SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
[So] Source:Arch Pathol Lab Med;141(10):1428-1433, 2017 Oct.
[Is] ISSN:1543-2165
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:SATB2 is part of the family of matrix attachment region-binding transcription factors, and has developmental roles in craniofacial, neural, and osteoblastic differentiation. Recently, SATB2 has been shown to be highly expressed in the epithelium of the lower gastrointestinal tract, with a relatively narrow expression profile in malignancies, including colorectal/appendiceal adenocarcinomas, tumors of osteoblastic differentiation, and renal/urothelial carcinomas. SATB2 has gained interest as a relatively specific marker of colorectal differentiation, with potential applications including determining origin of adenocarcinomas of unknown primary and distinguishing primary ovarian mucinous adenocarcinomas from colorectal metastases. Here, we briefly review the biology, expression profile, and potential histologic applications of SATB2.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico
Biomarcadores Tumorais/análise
Neoplasias Colorretais/diagnóstico
Proteínas de Ligação à Região de Interação com a Matriz/análise
Fatores de Transcrição/análise
[Mh] Termos MeSH secundário: Seres Humanos
Imuno-Histoquímica
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (Matrix Attachment Region Binding Proteins); 0 (SATB2 protein, human); 0 (Transcription Factors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171020
[Lr] Data última revisão:
171020
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.5858/arpa.2016-0243-RS


  6 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28937318
[Au] Autor:Kucuksayan H; Akca H
[Ad] Endereço:Department of Medical Biology, School of Medicine, Pamukkale University, Denizli, Turkey.
[Ti] Título:The crosstalk between p38 and Akt signaling pathways orchestrates EMT by regulating SATB2 expression in NSCLC cells.
[So] Source:Tumour Biol;39(9):1010428317706212, 2017 Sep.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Epithelial-mesenchymal transition is a crucial event for metastasis and could be mediated by several pathways such as phosphoinositide 3-kinase/Akt, mitogen-activated protein kinases, as well as many epigenetic regulators. Special AT-rich sequence-binding protein 2 is an epigenetic regulator involved in epithelial-mesenchymal transition and osteoblastic differentiation. It has been reported that the crosstalk between several pathways is responsible for the regulation of epithelial-mesenchymal transition in cancer cells. However, crosstalks between p38 and Akt pathways involved in epithelial-mesenchymal transition are still unknown. We recently reported that there is a crosstalk between p38 and Akt pathways in non-small-cell lung carcinoma cells, and this crosstalk is associated with E-cadherin and special AT-rich sequence-binding protein 2 expressions. Therefore, we aimed to determine whether this crosstalk has a mediator role in the regulation of epithelial-mesenchymal transition in non-small-cell lung carcinoma. Our results showed that inhibition of p38 leads to the disruption of this crosstalk via decreased expression of phosphatase and tensin homolog (PTEN) and subsequently increased activation of Akt in non-small-cell lung carcinoma cells. Then, we found that p38 inhibition upregulated special AT-rich sequence-binding protein 2 expression and reversed epithelial-mesenchymal transition in non-small-cell lung carcinoma cells. Furthermore, special AT-rich sequence-binding protein 2 knockdown abolished the effect of p38 inhibition on epithelial-mesenchymal transition in non-small-cell lung carcinoma cells. In conclusion, our results strongly indicate that the crosstalk between p38 and Akt pathways can determine special AT-rich sequence-binding protein 2 expression and epithelial character of non-small-cell lung carcinoma cells, and special AT-rich sequence-binding protein 2 is a critical epigenetic regulator for epithelial-mesenchymal transition mediated by p38 pathway in non-small-cell lung carcinoma. Our findings will contribute to illuminate the molecular mechanisms of the epithelial-mesenchymal transition process that has a critical significance for lung cancer metastasis.
[Mh] Termos MeSH primário: Carcinoma Pulmonar de Células não Pequenas/patologia
Transição Epitelial-Mesenquimal/fisiologia
Neoplasias Pulmonares/patologia
Proteínas de Ligação à Região de Interação com a Matriz/biossíntese
Receptor Cross-Talk/fisiologia
Fatores de Transcrição/biossíntese
[Mh] Termos MeSH secundário: Western Blotting
Carcinoma Pulmonar de Células não Pequenas/metabolismo
Linhagem Celular Tumoral
Regulação Neoplásica da Expressão Gênica/fisiologia
Técnicas de Silenciamento de Genes
Seres Humanos
Neoplasias Pulmonares/metabolismo
Sistema de Sinalização das MAP Quinases/fisiologia
PTEN Fosfo-Hidrolase/metabolismo
Proteínas Proto-Oncogênicas c-akt/metabolismo
Transdução de Sinais/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Matrix Attachment Region Binding Proteins); 0 (SATB2 protein, human); 0 (Transcription Factors); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 3.1.3.67 (PTEN Phosphohydrolase); EC 3.1.3.67 (PTEN protein, human)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171017
[Lr] Data última revisão:
171017
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317706212


  7 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28711650
[Au] Autor:Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
[Ad] Endereço:Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232. Electronic address: giovanna.giannico@vanderbilt.edu.
[Ti] Título:Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
[So] Source:Hum Pathol;67:152-159, 2017 Sep.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The differential diagnosis of glandular lesions of the bladder/urinary tract can be challenging because of significant morphologic and immunohistochemical overlap between primary lesions and metastasis/direct extension from adjacent organs. Special AT-rich sequence-binding protein 2 (SATB2), encoded on chromosome 2q32-33, is a recently described DNA-binding protein involved in osteoblast lineage commitment and expressed in colorectal and appendiceal neoplasms. In this study, we hypothesized that immunohistochemistry for SATB2 may be of value in distinguishing primary adenocarcinoma of the bladder/urinary tract and urothelial carcinoma with glandular differentiation from gastrointestinal and endocervical primaries. Intensity and distribution of SATB2 nuclear labeling were semiquantitatively scored and compared with those of CDX2. The study included 43 primary adenocarcinomas of the bladder/urinary tract, 20 urothelial carcinomas with glandular differentiation, 26 adenocarcinomas of the uterine cervix, and 22 colorectal adenocarcinomas involving the bladder. Positive SATB2 immunostaining was observed in 21 of 43 (49%) primary bladder/urinary tract adenocarcinomas, in 17 of 22 (77%) colorectal adenocarcinomas, and in the glandular component of 4 of 18 (22%) urothelial carcinomas with glandular differentiation. SATB2 was negative in 25 of 26 endocervical adenocarcinomas and showed focal weak immunostaining (1+) in 1 of 26 (4%). The results were not significantly different from those seen with CDX2. We conclude that SATB2 immunohistochemistry is not useful in supporting urothelial versus gastrointestinal or endocervical origin in the differential diagnosis of glandular lesions of the bladder/urinary tract.
[Mh] Termos MeSH primário: Adenocarcinoma/química
Biomarcadores Tumorais/análise
Linhagem da Célula
Neoplasias Colorretais/química
Proteínas de Ligação à Região de Interação com a Matriz/análise
Fatores de Transcrição/análise
Neoplasias da Bexiga Urinária/química
Urotélio/química
Neoplasias do Colo do Útero/química
[Mh] Termos MeSH secundário: Adenocarcinoma/secundário
Fator de Transcrição CDX2/análise
Diferenciação Celular
Neoplasias Colorretais/patologia
Bases de Dados Factuais
Diagnóstico Diferencial
Feminino
Seres Humanos
Imuno-Histoquímica
Valor Preditivo dos Testes
Prognóstico
Estudos Retrospectivos
Neoplasias da Bexiga Urinária/secundário
Urotélio/patologia
Neoplasias do Colo do Útero/patologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CDX2 Transcription Factor); 0 (CDX2 protein, human); 0 (Matrix Attachment Region Binding Proteins); 0 (SATB2 protein, human); 0 (Transcription Factors)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170717
[St] Status:MEDLINE


  8 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28627136
[Au] Autor:Drakouli S; Lyberopoulou A; Papathanassiou M; Mylonis I; Georgatsou E
[Ad] Endereço:Laboratory of Biochemistry, Faculty of Medicine, University of Thessaly, Volos, Greece.
[Ti] Título:Enhancer of rudimentary homologue interacts with scaffold attachment factor B at the nuclear matrix to regulate SR protein phosphorylation.
[So] Source:FEBS J;284(15):2482-2500, 2017 Aug.
[Is] ISSN:1742-4658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Scaffold attachment factor B1 (SAFB1) is an integral component of the nuclear matrix of vertebrate cells. It binds to DNA on scaffold/matrix attachment region elements, as well as to RNA and a multitude of different proteins, affecting basic cellular activities such as transcription, splicing and DNA damage repair. In the present study, we show that enhancer of rudimentary homologue (ERH) is a new molecular partner of SAFB1 and its 70% homologous paralogue, scaffold attachment factor B2 (SAFB2). ERH interacts directly in the nucleus with the C-terminal Arg-Gly-rich region of SAFB1/2 and co-localizes with it in the insoluble nuclear fraction. ERH, a small ubiquitous protein with striking homology among species and a unique structure, has also been implicated in fundamental cellular mechanisms. Our functional analyses suggest that the SAFB/ERH interaction does not affect SAFB1/2 function in transcription (e.g. as oestrogen receptor α co-repressors), although it reverses the inhibition exerted by SAFB1/2 on the splicing kinase SR protein kinase 1 (SRPK1), which also binds on the C-terminus of SAFB1/2. Accordingly, ERH silencing decreases lamin B receptor and SR protein phosphorylation, which are major SRPK1 substrates, further substantiating the role of SAFB1 and SAFB2 in the co-ordination of nuclear function.
[Mh] Termos MeSH primário: Proteínas de Ciclo Celular/metabolismo
Proteínas de Ligação à Região de Interação com a Matriz/metabolismo
Proteínas Associadas à Matriz Nuclear/metabolismo
Processamento de Proteína Pós-Traducional
Proteínas Serina-Treonina Quinases/metabolismo
Receptores Estrogênicos/metabolismo
Fatores de Processamento de Serina-Arginina/metabolismo
Fatores de Transcrição/metabolismo
[Mh] Termos MeSH secundário: Transporte Ativo do Núcleo Celular
Animais
Proteínas de Ciclo Celular/antagonistas & inibidores
Proteínas de Ciclo Celular/química
Proteínas de Ciclo Celular/genética
Linhagem Celular Tumoral
Genes Reporter
Proteínas de Fluorescência Verde/genética
Proteínas de Fluorescência Verde/metabolismo
Células HEK293
Seres Humanos
Proteínas de Ligação à Região de Interação com a Matriz/química
Proteínas de Ligação à Região de Interação com a Matriz/genética
Microscopia de Fluorescência
Proteínas Associadas à Matriz Nuclear/química
Proteínas Associadas à Matriz Nuclear/genética
Fragmentos de Peptídeos/química
Fragmentos de Peptídeos/genética
Fragmentos de Peptídeos/metabolismo
Fosforilação
Domínios e Motivos de Interação entre Proteínas
Multimerização Proteica
Proteínas Serina-Treonina Quinases/antagonistas & inibidores
Proteínas Serina-Treonina Quinases/química
Proteínas Serina-Treonina Quinases/genética
Interferência de RNA
Ratos
Receptores Estrogênicos/química
Receptores Estrogênicos/genética
Proteínas Recombinantes de Fusão/química
Proteínas Recombinantes de Fusão/metabolismo
Fatores de Processamento de Serina-Arginina/química
Fatores de Transcrição/antagonistas & inibidores
Fatores de Transcrição/química
Fatores de Transcrição/genética
Técnicas do Sistema de Duplo-Híbrido
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cell Cycle Proteins); 0 (ERH protein, human); 0 (Matrix Attachment Region Binding Proteins); 0 (Nuclear Matrix-Associated Proteins); 0 (Peptide Fragments); 0 (Receptors, Estrogen); 0 (Recombinant Fusion Proteins); 0 (SAFB protein, human); 0 (SAFB2 protein, human); 0 (Transcription Factors); 147336-22-9 (Green Fluorescent Proteins); 170974-22-8 (Serine-Arginine Splicing Factors); EC 2.7.1.- (SRPK1 protein, human); EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE
[do] DOI:10.1111/febs.14141


  9 / 488 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28438615
[Au] Autor:Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
[Ad] Endereço:Department of Diagnostic Pathology, Chiba University Graduate School of Medicine, Chiba 260-8677, Japan. Electronic address: jmatsushima@chiba-u.jp.
[Ti] Título:Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and ß-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
[So] Source:Hum Pathol;64:179-185, 2017 Jun.
[Is] ISSN:1532-8392
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Pulmonary enteric adenocarcinoma (PEA) is a rare variant of pulmonary adenocarcinoma; it is sometimes difficult to discriminate between PEA and metastatic colorectal carcinoma (MCRC) because of their morphological and immunohistochemical resemblance. Here, we conducted clinicopathological, immunohistochemical, and mutational analyses of PEA with special focus on its differentiation from MCRC. We comparatively analyzed 8 surgically resected PEA tumors (7 patients) and 20 cases of MCRC. Patients were aged 43-77 years (average age, 64.1 years); 5 of 7 patients were men. Tumor sizes ranged from 1.5 to 11.5 cm (average size, 4.8 cm). The follow-up period was 1-65 months; 4 patients are alive without recurrence, 2 are alive with recurrence, and 1 patient died of idiopathic pulmonary fibrosis. Six of the tumors were pure PEA; one PEA tumor had a small mucinous adenocarcinoma component; another had a squamous cell carcinoma component. Immunohistochemically, the positive rates of PEA for each antibody were as follows: CK7, 88% (7/8); CK20, 88% (7/8); TTF-1, 13% (1/8); ß-catenin, 0% (0/8, strong nuclear expression); and SATB2, 13% (1/8). The positive rates of MCRC for these antibodies were 10%, 95%, 5%, 55%, and 100%, respectively. Genetic analysis of KRAS, EGFR, and BRAF showed the G12V mutation in exon 2 of KRAS in 1 PEA. The present study's findings indicate that ß-catenin and SATB2 are useful immunohistochemical markers for differentiating between PEA and MCRC.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico
Biomarcadores Tumorais
Neoplasias Colorretais/diagnóstico
Análise Mutacional de DNA
Imuno-Histoquímica
Neoplasias Pulmonares/diagnóstico
Proteínas de Ligação à Região de Interação com a Matriz/análise
Mutação
Proteínas Proto-Oncogênicas p21(ras)/genética
Fatores de Transcrição/análise
beta Catenina/análise
[Mh] Termos MeSH secundário: Adenocarcinoma/química
Adenocarcinoma/genética
Adenocarcinoma/patologia
Adulto
Idoso
Biomarcadores Tumorais/análise
Biomarcadores Tumorais/genética
Biópsia
Neoplasias Colorretais/química
Neoplasias Colorretais/genética
Neoplasias Colorretais/patologia
Diagnóstico Diferencial
Éxons
Feminino
Predisposição Genética para Doença
Seres Humanos
Neoplasias Pulmonares/química
Neoplasias Pulmonares/genética
Neoplasias Pulmonares/secundário
Masculino
Meia-Idade
Fenótipo
Valor Preditivo dos Testes
Carga Tumoral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CTNNB1 protein, human); 0 (KRAS protein, human); 0 (Matrix Attachment Region Binding Proteins); 0 (SATB2 protein, human); 0 (Transcription Factors); 0 (beta Catenin); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170426
[St] Status:MEDLINE


  10 / 488 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28345457
[Au] Autor:Ma J; Wu K; Zhao Z; Miao R; Xu Z
[Ad] Endereço:1 Department of Thoracic Surgery, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, P.R. China.
[Ti] Título:Special AT-rich sequence binding protein 1 promotes tumor growth and metastasis of esophageal squamous cell carcinoma.
[So] Source:Tumour Biol;39(3):1010428317694537, 2017 Mar.
[Is] ISSN:1423-0380
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Esophageal squamous cell carcinoma is one of the most aggressive malignancies worldwide. Special AT-rich sequence binding protein 1 is a nuclear matrix attachment region binding protein which participates in higher order chromatin organization and tissue-specific gene expression. However, the role of special AT-rich sequence binding protein 1 in esophageal squamous cell carcinoma remains unknown. In this study, western blot and quantitative real-time polymerase chain reaction analysis were performed to identify differentially expressed special AT-rich sequence binding protein 1 in a series of esophageal squamous cell carcinoma tissue samples. The effects of special AT-rich sequence binding protein 1 silencing by two short-hairpin RNAs on cell proliferation, migration, and invasion were assessed by the CCK-8 assay and transwell assays in esophageal squamous cell carcinoma in vitro. Special AT-rich sequence binding protein 1 was significantly upregulated in esophageal squamous cell carcinoma tissue samples and cell lines. Silencing of special AT-rich sequence binding protein 1 inhibited the proliferation of KYSE450 and EC9706 cells which have a relatively high level of special AT-rich sequence binding protein 1, and the ability of migration and invasion of KYSE450 and EC9706 cells was distinctly suppressed. Special AT-rich sequence binding protein 1 could be a potential target for the treatment of esophageal squamous cell carcinoma and inhibition of special AT-rich sequence binding protein 1 may provide a new strategy for the prevention of esophageal squamous cell carcinoma invasion and metastasis.
[Mh] Termos MeSH primário: Carcinoma de Células Escamosas/patologia
Movimento Celular/genética
Proliferação Celular/genética
Neoplasias Esofágicas/patologia
Proteínas de Ligação à Região de Interação com a Matriz/genética
[Mh] Termos MeSH secundário: Carcinoma de Células Escamosas/genética
Linhagem Celular Tumoral
Neoplasias Esofágicas/genética
Seres Humanos
Invasividade Neoplásica/genética
Interferência de RNA
RNA Interferente Pequeno/genética
Reação em Cadeia da Polimerase em Tempo Real
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Matrix Attachment Region Binding Proteins); 0 (RNA, Small Interfering); 0 (SATB1 protein, human)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170407
[Lr] Data última revisão:
170407
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170328
[St] Status:MEDLINE
[do] DOI:10.1177/1010428317694537



página 1 de 49 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde